Nutrition Research and Practice

The Korean Nutrition Society (한국영양학회)
권호 표지

Effect of Coenzyme Q10 and green tea on plasma and liver lipids, platelet aggregation, TBARS production and erythrocyte Na leak in simvastatin treated hypercholesterolmic rats

  • Kim, Yang-Hee (Department of Foods & Nutrition, Cheju National University) ;
  • Moon, Young-In (Jeju Agricultural Development and Technology Extention Center) ;
  • Kang, Young-Hee (Division of life Sciences and Institute of Environment and Life Science, Hallym University) ;
  • Kang, Jung-Sook (Department of Foods & Nutrition, Cheju National University)
  • Published : 2007.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

This study was conducted to investigate the hypocholesterolemic effect of simvastatin (30 mg/kg BW) and antioxidant effect of coenzyme Q10 (CoQ10, 15 mg/kg BW) or green tea (5%) on erythrocyte Na leak, platelet aggregation and TBARS production in hypercholesterolemic rats treated with statin. Food efficiency ratio (FER, ADG/ADFI) was decreased in statin group and increased in green tea group, and the difference between these two groups was significant (p<0.05). Plasma total cholesterol was somewhat increased in all groups with statin compared with control. Plasma triglyceride was decreased in statin group and increased in groups of CoQ10 and green tea, and the difference between groups of statin and green tea was significant (p<0.05). Liver total cholesterol was not different between the control and statin group, but was significantly decreased in the group with green tea compared with other groups (p<0.05). Liver triglyceride was decreased in groups of statin and green tea compared with the control, and the difference between groups of the control and green tea was significant (p<0.05). Platelet aggregation of both the initial slope and the maximum was not significantly different, but the group with green tea tended to be higher in initial slope and lower in the maximum. Intracellular Na of group with green tea was significantly higher than the control or statin group (p<0.05). Na leak in intact cells was significantly decreased in the statin group compared with the control (p<0.05). Na leak in AAPH treated cells was also significantly reduced in the statin group compared with groups of the control and CoQ10 (p<0.05). TBARS production in platelet rich plasma was significantly decreased in the groups with CoQ10 and green tea compared with the control and statin groups (p<0.05). TBARS of liver was significantly decreased in the group with green tea compared with the statin group (p<0.05). In the present study, even a high dose of statin did not show a cholesterol lowering effect, therefore depletion of CoQ10 following statin treatment in rats is not clear. More clinical studies are needed for therapeutic use of CoQ10 as an antioxidant in prevention of degenerative diseases independent of statin therapy.

Keywords

References

  1. Aggarwal D, West KL, Zern TL, Shrestha S & Fernandez ML (2005). JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs. BMC Cardiovasc Disord. 27; 5:30:1-8
  2. Akiba T, Shibuta T, Amano Y, Koga T & Takimoto M (1999). 28-day repeated oral toxicity study of a hypolipidemic agent, NK-104 in rats. J Toxicol Sci 5:701-711
  3. Bandoh T, Mitani H, Niihashi M, Totsuka T, Sakurai I & Hayashi S (2000). Fluvastatin suppresses atherosclerotic progression, mediated through its inhibitory effect on endothelial dysfunction, lipid peroxidation, and macrophage deposition. J Cardiovasc Pharmacol 35:136-144 https://doi.org/10.1097/00005344-200001000-00018
  4. Broncel M, Koter-Michalak M & Chojnowska-Jezierska J (2006). The effect of statins on lipids peroxidation and activities of antioxidants enzymes in patients with dyslipidemia. Przegl Lek 63:738-742
  5. Broncel M, Balcerak M, Sikora J & Chojnowska-Jezierska J (2007). Effect of fluvastatin extended release on the protein-lipid structure of erythrocyte membrane and C-reactive protein in patients with hyperlipidemia. Polski merkuriusz lekarski 22:107-111
  6. Dajani EZ, Shahwan TG & Dajani NE (2002). Statins, platelet aggregation and coronary heart disease. J Assoc Acad Minor Phys 13:27-31
  7. Davis HR Jr, Pula KK, Burrier RE & Watkins RW (2001). The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibitors in dogs. Metabolism 50:1234-1241 https://doi.org/10.1053/meta.2001.26737
  8. Dhanasekaran M & Ren J (2005). The emerging role of coenzyme Q-10 in aging, neurodegeneration, cardiovascular disease, cancer and diabetes mellitus. Curr Neurovasc Res 2:447-459 https://doi.org/10.2174/156720205774962656
  9. Dietscht JM, Turley SD & Spady DK (1993). Role of the liver in the maintenance of cholesterol and low density lipoprotein in homeostasis in different animal species including human. J Lipid Res 34:1637-1659
  10. Draper HH & Callant AS (1969). A simplified hemolysis test for vitamin E deficiency. J Nutr 98:390-394 https://doi.org/10.1093/jn/98.4.390
  11. Famer D & Crisby M (2007). Rosuvastatin reduces gliosis and the accelerated weight gain observed in WT and ApoE-l- mice exposed to a high cholesterol diet. Neurosci Lett. 419:68-73 https://doi.org/10.1016/j.neulet.2007.03.055
  12. Fernandez ML (2001). Guinea pigs as models for cholesterol and lipoprotein metabolism. J Nutr 131:10-20
  13. Folch J, Lee M & Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226:497-509
  14. Galus R, Włodarski P & Włodarski K (2006) Influence of fluvastatin on bone formation induced by demineralized bone matrix in mice. Pharmacol Rep 58:443-447
  15. Haramaki N, Ikeda H, Takenaka K, Matsuoka H & Imaizumi T (2007) Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: possible improvement of intraplatelet redox imbalance via HMG-CoA reductase. Arteriosclerm Thromb Vascular Biol. 27:1471-1477 https://doi.org/10.1161/ATVBAHA.106.128793
  16. Kaneta S, Satoh K, Kanda M & Ichihara K (2003). All hydrophobic HMG coA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cell. Athrosclerosis 170:237-243 https://doi.org/10.1016/S0021-9150(03)00301-0
  17. Kang JS, Cregor MD & Smith JB (1990). Effect of calcium on blood pressure, platelet aggregation and erythrocyte sodium transport in Dahl salt-sensitive rats. J Hypertens. 8:245-250
  18. King DE, Mainous AG, Player A & Geesey ME (2007). Use of statins and blood pressure. Am J Hypertens 20:937-941 https://doi.org/10.1016/j.amjhyper.2007.03.018
  19. Lamperti C, Naini AB, Lucchini V, Moggio M, Sciacco M, Kaufmann P & DiMauro S (2005). Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol 62:1709-1712 https://doi.org/10.1001/archneur.62.11.1709
  20. Lankas GR, Cukierski MA & Wise LD (2004). The role of maternal toxicity in lovastatin-induced developmental toxicity. Birth Defects Res B Dev Reprod Toxicol 71:111-123 https://doi.org/10.1002/bdrb.20005
  21. Littarru GP & Langsjoen P (2007). Coenzyme Q10 and statins: biochemical and clinical implications. Mitochondrion 7:168-174 https://doi.org/10.1016/j.mito.2007.03.002
  22. Liu CH, Huang MT & Huang PC (1995). Source of triglyceride accumulation in livers of rats fed a cholesterol supplemented diet. Lipids 30:527-531 https://doi.org/10.1007/BF02537027
  23. Mabuchi H, Higashikata T, Kawashiri M, Inazu A, Koizumi J & Kobayashi J (2005). Reduction of serum ubiquinol-10 and ubiquinone- 10 levels by atorvastatin in hypercholesterolemic patients. J Atheroscler Thromb 12:111-119 https://doi.org/10.5551/jat.12.111
  24. Mabuchi H, Nohara A, Katsuda S, Inatsuda S & Koizumi J (2007). Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized doubleblind study. Lipid Research 195:e182-189
  25. Maridonneau I, Braquet P &, Garay RP (1983). Na+ and K+ transport damage induced by oxygen free radicals in human red blood cell membranes. Biol Chem 285:3107-3113
  26. Mason RP, Walter MF, Day CA & Jacob RF (2006). Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism. J Biol Chem 281:9337-9345 https://doi.org/10.1074/jbc.M513000200
  27. Matsuno H, Takei M, Hayashi H, Nakajima K & Kozawa O (2004). Simvastatin enhances the regeneration of endothelial cells via VEGF secretion in injured arteries. J Cardiovasc Pharmacol 43:333-340 https://doi.org/10.1097/00005344-200403000-00002
  28. Mitane Y, Miwa Sagesaka M & Okada S (1990). Platelet aggregation inhibitors in hot water extract of green tea. Chem Pharm Bull 38:790-793 https://doi.org/10.1248/cpb.38.790
  29. Naseem KM & Bruckdorfer KR (1999). The influence of organic peroxides on platelet aggregation and sensitivity to nitric oxide. Platelets 10:146-152 https://doi.org/10.1080/09537109976220
  30. Nawarskas JJ (2005) HMG-CoA reductase inhibitors and coenzyme Q10. Cardiol Rev 13:76-79 https://doi.org/10.1097/01.crd.0000154790.42283.a1
  31. Osada K, Takahashi M, Hoshina S, Nakamura S & Sugano M (2001) Tea catechins inhibit cholesterol oxidation accompanying oxidation of low density lipoprotein in vitro. Comp Biochem Physiol C Toxicol Pharmacol 128:153-164 https://doi.org/10.1016/S1532-0456(00)00192-7
  32. Pentaceska SS, DeRosa S, Olm V, Diaz N, Pappolla M & Refolo LM (2002). Statin therapy for alzheimer' disease; will it work? J Mol Neurisci 10:155-161
  33. Raederstorff DG, Schlachter MF, Elste V & Weber P (2003) Effect of EGCG on lipid absorption and plasma lipid levels in rats. J Nutr Biochem 14:326-332 https://doi.org/10.1016/S0955-2863(03)00054-8
  34. Ryszawa N, Kawczyńska-Drózdz A, Adamek-Guzik T, Korbut R & Guzik TJ (2006). Effects of novel plant antioxidants on platelet superoxide production and aggregation in atherosclerosis. J Physiol Pharmacol 57:611-626
  35. Saffari Y & Sadrzadeh SM (2004). Green tea metabolite EGCG protects membranes against oxidative damage in vitro. Life Sci 6; 74:1513-1518 https://doi.org/10.1016/0024-3205(67)90331-1
  36. Sawada M, Matsuo M & Seki J (2002). Inhibition of cholesterol synthesis causes both hypercholesterolemia and hypocholesterolemia in hamsters. Biol Pharm Bull 25:1577-1582 https://doi.org/10.1248/bpb.25.1577
  37. Sayama K, Lin SX, Zheng GD & Oguni I (2003). Antiobee effects of green tea powder and its components. International Symposium on Green tea. KFN Conference, 7:55-62
  38. Staal A, Frith JC, Fewnch MH, Stuwartz J, Rogers MJ & Feyen JH (2003) The ability of statins to inhibit bone reabsorption is directly related to their inhibitory effect on HMG coA reductase activity. J Bone Mineral Res 18:88-96 https://doi.org/10.1359/jbmr.2003.18.1.88
  39. Susic D, Varagic J, Ahn J, slama M & Frohlich ED (2003). Beneficial pleitropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol 42:1091-1097 https://doi.org/10.1016/S0735-1097(03)00926-4
  40. Tavintharan S, Ong CN, Sivakumar M, Lim SC & Sum CF (2007). Reduced mitochondrial coenzyme Q10 levels in HepG2 cells treated with high-dose simvastatin: a possible role in statin-induced hepatotoxicity? Toxicol Appl Pharmacol 223:173-179 https://doi.org/10.1016/j.taap.2007.05.013
  41. Terao J, Piskula M & Yao Q. (1994) Protective effect of epicatechin, epicatechin gallate, and quercetin on lipid peroxidation in phospholipid bilayers.. Arch Biochem Biophys 308:278-284 https://doi.org/10.1006/abbi.1994.1039
  42. Tziakas DN, Kaski JC, Chalikias GK, Bomero C, Hatseras DI & Holt DW (2007). Total cholesterol content of erythrocyte membranes is increased in patients with acute coronary syndrome: a new marker of clinical instability. J Am Coll Cardiol 49:2081-2089 https://doi.org/10.1016/j.jacc.2006.08.069
  43. Uyuklu M, Meiselman HJ & Baskurt OK (2007). Effect of decreased plasma cholesterol by atorvastatin treatment on erythrocyte mechanical properties. Clin Hemorheol Microcirc 36:25-33
  44. Villa E, Rábano A, Albarrán OG, Ruilope LM & García-Robles R (1998). Effects of chronic combined treatment with captopril and pravastatin on the progression of insulin resistance and cardiovascular alterations in an experimental model of obesity in dogs. Am J Hypertens 11:844-851 https://doi.org/10.1016/S0895-7061(98)00053-3
  45. West KL & Fernandez ML (2004). Guinea pigs as models to study the hypocholesterolemic effects of drugs. Cardiovasc Drug Rev. 22:55-70 https://doi.org/10.1111/j.1527-3466.2004.tb00131.x
  46. Zacco A Togo J, Spence K, Furlong S & Piser T (2003). HMG CoA reductase inhibitor protect cortical neurons from excitotoxicity. J Neurosci 23:11104-11111 https://doi.org/10.1523/JNEUROSCI.23-35-11104.2003